Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Prime Medicine (PRME) Invested Capital (2021 - 2025)

Prime Medicine's Invested Capital history spans 5 years, with the latest figure at $120.9 million for Q4 2025.

  • For Q4 2025, Invested Capital fell 21.08% year-over-year to $120.9 million; the TTM value through Dec 2025 reached $120.9 million, down 21.08%, while the annual FY2025 figure was $120.9 million, 21.08% down from the prior year.
  • Invested Capital reached $120.9 million in Q4 2025 per PRME's latest filing, down from $161.8 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $316.3 million in Q4 2022 to a low of -$223.1 million in Q3 2022.
  • Average Invested Capital over 5 years is $86.7 million, with a median of $143.1 million recorded in 2023.
  • The largest YoY upside for Invested Capital was 302.43% in 2022 against a maximum downside of 136.29% in 2022.
  • A 5-year view of Invested Capital shows it stood at -$156.2 million in 2021, then soared by 302.43% to $316.3 million in 2022, then plummeted by 57.92% to $133.1 million in 2023, then grew by 15.09% to $153.1 million in 2024, then dropped by 21.08% to $120.9 million in 2025.
  • Per Business Quant, the three most recent readings for PRME's Invested Capital are $120.9 million (Q4 2025), $161.8 million (Q3 2025), and $60.9 million (Q2 2025).